Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Dividends Paid - Common (2017 - 2025)

Historic Dividends Paid - Common for Fortress Biotech (FBIO) over the last 9 years, with Q3 2025 value amounting to $166000.0.

  • Fortress Biotech's Dividends Paid - Common changed N/A to $166000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $498000.0, marking a year-over-year decrease of 9173.31%. This contributed to the annual value of $4.0 million for FY2024, which is 5000.0% down from last year.
  • Fortress Biotech's Dividends Paid - Common amounted to $166000.0 in Q3 2025.
  • Fortress Biotech's 5-year Dividends Paid - Common high stood at $2.0 million for Q4 2021, and its period low was $166000.0 during Q1 2025.
  • In the last 5 years, Fortress Biotech's Dividends Paid - Common had a median value of $188000.0 in 2021 and averaged $1.0 million.
  • Per our database at Business Quant, Fortress Biotech's Dividends Paid - Common skyrocketed by 98540.54% in 2024 and then plummeted by 9173.31% in 2025.
  • Over the past 5 years, Fortress Biotech's Dividends Paid - Common (Quarter) stood at $2.0 million in 2021, then fell by 0.05% to $2.0 million in 2022, then grew by 0.05% to $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then crashed by 91.73% to $166000.0 in 2025.
  • Its Dividends Paid - Common was $166000.0 in Q3 2025, compared to $166000.0 in Q2 2025 and $166000.0 in Q1 2025.